Compare Cintas Corporation (CTAS) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Tempus AI — how do they compare? Cintas Corporation trades at $200.75 (market cap $79.86B), while Tempus AI trades at $70.3 (market cap $12.58B). The key difference: Cintas Corporation is far larger — about 6.3× Tempus AI's market cap, and Cintas Corporation pays a 1.03% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 124 Days and Tempus AI for 22 Days on average.
| CTAS | TEM | |
|---|---|---|
Market Cap | $79.86B | $12.58B |
Volume | 1,323,583 | 7,444,569 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $216.53 | $99.28 |
52-Week Low | $163.55 | $41.55 |
Typical Hold Time | 124 Days | 22 Days |
Enterprise Value | $82.33B | $13.21B |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $197.19, up 0.63% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2027 results with revenue of $3.01 billion, beating estimates, and raised full-year guidance. Fundamentals show robust revenue growth, expanding margins, and high profitability, though valuation multiples like a P/E of 39.67 are elevated. Analyst sentiment is moderately bullish with a consensus price target of $234.60.
The outlook for CTAS is positive, driven by durable growth, record margins, and strong capital returns. Key opportunities include consistent earnings beats and market leadership, while risks involve high valuation sensitivity and competitive pressures. The stock's upside potential is supported by analyst targets, but investors should monitor execution against guidance.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
